Pape W J, Pfannenbecker U, Argembeaux H, Bracher M, Esdaile D J, Hagino S, Kasai Y, Lewis R W
Beiersdorf AG, Unnastrasse 48, D-20245 Hamburg, Germany (Lead Laboratory).
Toxicol In Vitro. 1999 Apr;13(2):343-54. doi: 10.1016/s0887-2333(98)00085-x.
The red blood cell test (RBC test) is part of the COLIPA Validation Project on Alternatives to Draize Eye Irritation. It shows good intra- and interlaboratory reproducibility (reliability) and represents one of the promising in vitro alternatives of this project with a good fit to prediction models (relevance) for the assessment of acute ocular irritancy caused by certain classes of chemicals (mainly surfactants) and formulations. Results obtained during the period of test development, prevalidation, and validation are summarized. The method is based on that of Pape et al. (1987), Pape and Hoppe (1990) and Lewis et al. (1993). The protocol has two endpoints: cellular lysis and changes in protein conformation which can be correlated with initial events in tissue injury inducing inflammatory responses as assessed by Draize eye irritation scoring. Both endpoints are detected by spectrophotometric changes in the haemoglobin absorption at 541nm. The protocol also includes a set of prediction models (PM). One PM is designed to predict three classes of irritancy (classification model) based on both endpoints and the three other PMs are designed to predict modified maximum average scores (MMAS) by algorithms based on data from cellular lysis only. These three PMs [with prediction intervals (PIs)] are: (i) for surfactant ingredients, (ii) for surfactant containing finished products, and (iii) for both groups together. The three PMs are based on a common algorithm derived from historic data. It is shown that PMs derived from historic data from several laboratories, by the same procedure, also produce a good fit with the presented data. Therefore, participating laboratories concluded that the protocol as used in this formal validation study can be considered to be validated for the estimation of acute eye irritation potential of surfactant-containing finished products.
红细胞试验(RBC试验)是欧洲化妆品工业协会(COLIPA)替代德雷兹眼刺激试验验证项目的一部分。它在实验室内和实验室间均显示出良好的可重复性(可靠性),是该项目中颇具前景的体外替代试验之一,与用于评估某些类化学品(主要是表面活性剂)和配方引起的急性眼刺激性的预测模型(相关性)拟合良好。总结了在试验开发、预验证和验证期间获得的结果。该方法基于帕佩等人(1987年)、帕佩和霍佩(1990年)以及刘易斯等人(1993年)的方法。该方案有两个终点:细胞裂解和蛋白质构象变化,这两者可与通过德雷兹眼刺激评分评估的诱导炎症反应的组织损伤初始事件相关。两个终点均通过541nm处血红蛋白吸收的分光光度变化来检测。该方案还包括一组预测模型(PM)。一个PM旨在基于两个终点预测三类刺激性(分类模型),另外三个PM旨在通过仅基于细胞裂解数据的算法预测修正的最大平均得分(MMAS)。这三个PM(带有预测区间(PI))分别为:(i)用于表面活性剂成分,(ii)用于含表面活性剂的成品,(iii)用于两者。这三个PM基于从历史数据得出的通用算法。结果表明,通过相同程序从多个实验室的历史数据得出的PM也与所呈现的数据拟合良好。因此,参与研究的实验室得出结论,本正式验证研究中使用的方案可被视为已通过验证,用于估计含表面活性剂成品的急性眼刺激潜力。